- Gilead Sciences ( NASDAQ: GILD ) will end a partnership with Matinas Biopharma ( NYSE: MTNB ) that aimed to develop an oral version of the COVID-19 therapy remdesivir.
- Gilead instead has decided to work on its own oral nucleoside prodrug of remdesivir.
- Starting at the end of 2020, Matinas ( MTNB ) began collaborating with the National Institute of Allergy and Infectious Diseases on its lipid nanocrystal ("LNC") platform to transform remdesivir, which is given via infusion, into a pill.
- Matinas ( MTNB ) also has a partnership with BioNTech ( BNTX ) that is expected to yield initial in vivo data in the first half of the year .
For further details see:
Gilead abandons oral version of COVID drug remdesivir with Matinas Biopharma